Logo image of CO

Global Cord Blood Corporation (CO) Stock Fundamental Analysis

USA - NYSE:CO - KYG393421030 - Common Stock

2.9876 USD
+0.77 (+34.58%)
Last: 9/23/2022, 8:04:01 PM
2.925 USD
-0.06 (-2.1%)
Pre-Market: 9/26/2022, 8:42:54 AM
Fundamental Rating

3

Overall CO gets a fundamental rating of 3 out of 10. We evaluated CO against 100 industry peers in the Health Care Providers & Services industry. The financial health of CO is average, but there are quite some concerns on its profitability. CO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CO was profitable.
Each year in the past 5 years CO has been profitable.
CO had a positive operating cash flow in each of the past 5 years.
CO Yearly Net Income VS EBIT VS OCF VS FCFCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

1.2 Ratios

Industry RankSector Rank
ROA 5.87%
ROE 10.27%
ROIC 6.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CO Yearly ROA, ROE, ROICCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2 4 6 8 10

1.3 Margins

Industry RankSector Rank
OM 48.97%
PM (TTM) 40.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CO Yearly Profit, Operating, Gross MarginsCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CO is destroying value.
Compared to 1 year ago, CO has about the same amount of shares outstanding.
There is no outstanding debt for CO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CO Yearly Shares OutstandingCO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CO Yearly Total Debt VS Total AssetsCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

CO has an Altman-Z score of 2.21. This is not the best score and indicates that CO is in the grey zone with still only limited risk for bankruptcy at the moment.
There is no outstanding debt for CO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACC0.73
WACC8.75%
CO Yearly LT Debt VS Equity VS FCFCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B

2.3 Liquidity

CO has a Current Ratio of 10.73. This indicates that CO is financially healthy and has no problem in meeting its short term obligations.
CO has a Quick Ratio of 10.66. This indicates that CO is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 10.73
Quick Ratio 10.66
CO Yearly Current Assets VS Current LiabilitesCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for CO have decreased by -1.41% in the last year.
Measured over the past 5 years, CO shows a small growth in Earnings Per Share. The EPS has been growing by 7.71% on average per year.
CO shows a small growth in Revenue. In the last year, the Revenue has grown by 7.21%.
The Revenue has been growing by 10.34% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.41%
EPS 3Y8.03%
EPS 5Y7.71%
EPS Q2Q%-18%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y8%
Revenue growth 5Y10.34%
Sales Q2Q%-1.69%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CO Yearly Revenue VS EstimatesCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B
CO Yearly EPS VS EstimatesCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 0.2 0.4 0.6 0.8 1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CO is valuated cheaply with a Price/Earnings ratio of 5.15.
When comparing the Price/Earnings ratio of CO to the average of the S&P500 Index (25.67), we can say CO is valued rather cheaply.
Industry RankSector Rank
PE 5.15
Fwd PE N/A
CO Price Earnings VS Forward Price EarningsCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.81
CO Per share dataCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.67
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Global Cord Blood Corporation

NYSE:CO (9/23/2022, 8:04:01 PM)

Premarket: 2.925 -0.06 (-2.1%)

2.9876

+0.77 (+34.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-15 2022-07-15/amc
Earnings (Next)10-11 2022-10-11/amc
Inst Owners0.03%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap400.08M
Revenue(TTM)1.24B
Net Income(TTM)501.06M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.15
Fwd PE N/A
P/S 2.29
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB N/A
EV/EBITDA -5.81
EPS(TTM)0.58
EY19.41%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.3
BVpS5.12
TBVpSN/A
PEG (NY)N/A
PEG (5Y)0.67
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 5.87%
ROE 10.27%
ROCE N/A
ROIC 6.39%
ROICexc N/A
ROICexgc 6.46%
OM 48.97%
PM (TTM) 40.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.73
Quick Ratio 10.66
Altman-Z 2.21
F-Score6
WACC8.75%
ROIC/WACC0.73
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.41%
EPS 3Y8.03%
EPS 5Y7.71%
EPS Q2Q%-18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.21%
Revenue growth 3Y8%
Revenue growth 5Y10.34%
Sales Q2Q%-1.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Global Cord Blood Corporation / CO FAQ

What is the ChartMill fundamental rating of Global Cord Blood Corporation (CO) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CO.


What is the valuation status for CO stock?

ChartMill assigns a valuation rating of 9 / 10 to Global Cord Blood Corporation (CO). This can be considered as Undervalued.


Can you provide the profitability details for Global Cord Blood Corporation?

Global Cord Blood Corporation (CO) has a profitability rating of 5 / 10.


Can you provide the financial health for CO stock?

The financial health rating of Global Cord Blood Corporation (CO) is 8 / 10.


How sustainable is the dividend of Global Cord Blood Corporation (CO) stock?

The dividend rating of Global Cord Blood Corporation (CO) is 0 / 10 and the dividend payout ratio is 0%.